ATE401404T1 - Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie - Google Patents

Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie

Info

Publication number
ATE401404T1
ATE401404T1 AT97952609T AT97952609T ATE401404T1 AT E401404 T1 ATE401404 T1 AT E401404T1 AT 97952609 T AT97952609 T AT 97952609T AT 97952609 T AT97952609 T AT 97952609T AT E401404 T1 ATE401404 T1 AT E401404T1
Authority
AT
Austria
Prior art keywords
ligand
kappa
receptor activator
tnf superfamily
receptors
Prior art date
Application number
AT97952609T
Other languages
English (en)
Inventor
Dirk Anderson
Laurent Galibert
Eugene Maraskovsky
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27369779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE401404(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE401404T1 publication Critical patent/ATE401404T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT97952609T 1996-12-23 1997-12-22 Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie ATE401404T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5997896P 1996-12-23 1996-12-23
US7718197P 1997-03-07 1997-03-07
US6467197P 1997-10-14 1997-10-14

Publications (1)

Publication Number Publication Date
ATE401404T1 true ATE401404T1 (de) 2008-08-15

Family

ID=27369779

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97953438T ATE497001T1 (de) 1996-12-23 1997-12-22 Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
AT97952609T ATE401404T1 (de) 1996-12-23 1997-12-22 Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT97953438T ATE497001T1 (de) 1996-12-23 1997-12-22 Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie

Country Status (13)

Country Link
US (21) US6242213B1 (de)
EP (5) EP0946725B1 (de)
JP (7) JP2002509431A (de)
AT (2) ATE497001T1 (de)
AU (2) AU713473B2 (de)
CA (1) CA2274987C (de)
DE (4) DE951551T1 (de)
DK (1) DK0951551T4 (de)
ES (1) ES2144386T5 (de)
IL (1) IL130492A (de)
LU (1) LU91758I2 (de)
PT (1) PT951551E (de)
WO (2) WO1998028426A2 (de)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050060764A1 (en) * 2003-09-17 2005-03-17 Susan Gregory Mouse model for bone metabolism
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6919434B1 (en) 1995-02-20 2005-07-19 Sankyo Co., Ltd. Monoclonal antibodies that bind OCIF
US7632922B1 (en) * 1995-12-22 2009-12-15 Amgen, Inc. Osteoprotegerin
US20050147611A1 (en) * 1995-12-22 2005-07-07 Amgen Inc. Combination therapy for conditions leading to bone loss
US6479254B2 (en) 1996-03-22 2002-11-12 Human Genome Sciences, Inc. Apoptosis inducing molecule II
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6495520B2 (en) 1996-03-22 2002-12-17 Human Genome Sciences, Inc. Apoptosis Inducing Molecule II and methods of use
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
BR9714401A (pt) * 1996-12-13 2000-04-18 Schering Corp Antìgenos de supefìcie de célula de mamìfero; regentes relacionados
ES2144386T5 (es) * 1996-12-23 2012-12-07 Immunex Corporation Ligando para el activador del receptor de NF-kappa b, el ligando es miembro de la superfamilia de TNF
CA2274803C (en) * 1996-12-23 2012-05-22 Immunex Corporation Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
WO1999058674A2 (en) 1998-05-14 1999-11-18 Immunex Corporation Method of inhibiting osteoclast activity
AU2008200700C1 (en) * 1997-04-15 2013-04-04 Daiichi Sankyo Co., Ltd Novel Protein and Process for Producing The Same
IL127115A (en) * 1997-04-15 2013-08-29 Daiichi Sankyo Co Ltd A substance for the treatment of diseases related to bone metabolism problem
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
ATE363533T1 (de) * 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
CA2229449A1 (en) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
AU7705098A (en) * 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
HUP0002062A3 (en) 1997-09-24 2002-09-30 Sankyo Co Method for diagnosing bone dysbolism
US7019119B2 (en) 1997-12-12 2006-03-28 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
WO1999029865A2 (en) * 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
US7063960B2 (en) * 1997-12-12 2006-06-20 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
PL196790B1 (pl) 1998-09-15 2008-01-31 Pharmexa As Zastosowanie zwierzęcego polipeptydu OPGL lub jego podsekwencji, lub analogu OPGL, zastosowanie fragmentu kwasu nukleinowego, zastosowanie wektora przenoszącego fragment kwasu nukleinowego, zastosowanie niepatogennej transformowanej komórki, zastosowanie kompozycji zawierającej taki fragment lub wektor, sposób identyfikacji zmodyfikowanego polipeptydu OPGL, sposób wytwarzania kompozycji immunogennej
EP1541587A3 (de) * 1998-09-15 2007-06-20 Pharmexa A/S Verfahren zur Hemmung der Wirkung von Osteoprotegerin-Ligand
US6534061B1 (en) 1999-04-12 2003-03-18 Genentech, Inc. Tumor necrosis factor receptor homologs and nucleic acids encoding the same
US6492124B1 (en) 1999-06-11 2002-12-10 The Rockefeller University Trance activated signal transduction pathways in osteoclasts
US6872806B1 (en) * 1999-06-25 2005-03-29 The Governors Of The University Of Alberta Polypeptide compositions formed using a coiled-coil template and methods of use
JP5118796B2 (ja) 1999-06-28 2013-01-16 ジェネンテック， インコーポレイテッド 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
JP4790179B2 (ja) * 1999-07-28 2011-10-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 破骨細胞活性を阻害する方法
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
US6171860B1 (en) * 1999-11-05 2001-01-09 Isis Pharmaceuticals, Inc. Antisense inhibition of rank expression
AU1920301A (en) * 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
GB9930616D0 (en) * 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
ATE511857T1 (de) 2000-02-16 2011-06-15 Genentech Inc Anti-april monoklonaler antikörper und deren verwendung zur behandlung von immunerkrankungen oder krebs
AU3868001A (en) † 2000-02-23 2001-09-03 Amgen Inc Antagonistic selective binding agents of osteoprotegerin binding protein
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
PL357939A1 (en) 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
JP2003534022A (ja) * 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体
ATE415978T1 (de) 2000-07-27 2008-12-15 Genentech Inc Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
WO2002016551A2 (en) * 2000-08-18 2002-02-28 University Of Massachusetts Medical Center Trance regulation of chondrocyte differentiation
WO2002015846A2 (en) * 2000-08-21 2002-02-28 Smithkline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
JP4854174B2 (ja) * 2000-09-22 2012-01-18 イミュネックス・コーポレーション ＮＦ−κＢの受容体活性化剤のアゴニストまたはアンタゴニストのスクリーニングアッセイ法
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US20040132971A1 (en) * 2001-02-09 2004-07-08 Haaning Jesper Mortensen Rank ligand-binding polypeptides
AU2002231602A1 (en) * 2001-02-09 2002-08-28 Maxygen Holdings Ltd. Rank ligand-binding polypeptides
JP2004526748A (ja) * 2001-03-22 2004-09-02 バーンズ − ジューウィッシュ・ホスピタル Ｒａｎｋリガンド融合タンパク質を使用する骨形成の刺激
US20030013651A1 (en) * 2001-03-22 2003-01-16 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
EP1412482A2 (de) * 2001-03-23 2004-04-28 Genentech, Inc. Verwendung einer opg ligand, um immunreaktionenen zu modulieren
US20040167072A1 (en) * 2001-05-11 2004-08-26 Aggarwal Bharat B. Inhibitors of receptor activator of NF-kappaB and uses thereof
US6998383B2 (en) * 2001-05-11 2006-02-14 Research Development Corporation Inhibitors of receptor activator of NF-κB and uses thereof
WO2002092016A2 (en) * 2001-05-17 2002-11-21 Immunex Corporation Therapeutic use of rank antagonists
US20040213788A1 (en) * 2001-05-18 2004-10-28 Sweet Raymond W. Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
WO2002098362A2 (en) * 2001-06-06 2002-12-12 Immunex Corporation Use of rank antagonists to treat cancer
WO2003002187A2 (en) * 2001-06-26 2003-01-09 Photomed Technologies, Inc. Multiple wavelength illuminator
JP4212470B2 (ja) 2001-06-26 2009-01-21 アムジェン フレモント インク． Ｏｐｇｌへの抗体
WO2003066661A2 (en) 2001-07-03 2003-08-14 Genentech, Inc. Human dr4 antibodies and uses thereof
US20030050223A1 (en) * 2001-08-09 2003-03-13 Jonathan Lam Crystal forms and mutants of RANK ligand
US20040186051A1 (en) 2001-10-02 2004-09-23 Kelley Robert F Apo-2 ligand variants and uses thereof
WO2003065972A2 (en) * 2001-10-12 2003-08-14 Barnes-Jewish Hospital Methods for screening osteogenic compounds
US20030100068A1 (en) * 2001-10-12 2003-05-29 Jonathan Lam RANKL mimics and uses thereof
US20030109444A1 (en) * 2001-10-12 2003-06-12 Jonathan Lam Bone anti-resorptive compounds
IL161387A0 (en) * 2001-10-15 2004-09-27 Barnes Jewish Hospital Rankl mimics and uses thereof
DE60237841D1 (de) 2001-11-13 2010-11-11 Genentech Inc Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
US20030166559A1 (en) * 2002-01-04 2003-09-04 Desjarlais John R. Dominant negative proteins and methods thereof
EP1560843A4 (de) * 2002-01-04 2006-09-06 Xencor Inc Neue varianten von rankl-protein
US20040170602A1 (en) * 2002-01-04 2004-09-02 Desjarlais John R. Dominant negative proteins and methods thereof
US7381792B2 (en) * 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
AU2003210054A1 (en) * 2002-03-21 2003-10-08 Komed Co., Ltd. Anti-rank monoclonal antibodies and pharmaceutical composition containing the same
PL375041A1 (en) 2002-04-05 2005-11-14 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
JP4574350B2 (ja) 2002-06-24 2010-11-04 ジェネンテック， インコーポレイテッド Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法
US20040138162A1 (en) * 2002-08-30 2004-07-15 Roodman G. David Method of resisting osteoclast formation
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
MXPA05006147A (es) 2002-12-10 2005-08-26 Schering Plough Ltd Ligando del activador del receptor de nf-kb de canino, y metodos para preparar y usar el mismo.
EP1582589B1 (de) * 2003-01-10 2010-03-24 Protein Crystal Co., Ltd. Proteinkomplex, verfahren zu dessen herstellung und verwendung davon
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005028633A2 (en) * 2003-09-17 2005-03-31 Isis Pharmaceuticals, Inc. Modulation of rankl expression
US7252833B2 (en) * 2003-11-18 2007-08-07 Skeletal Kinetics, Llc Calcium phosphate cements comprising an osteoclastogenic agent
EP1709450A2 (de) * 2003-12-29 2006-10-11 TOUDAI TLO, Ltd. Verfahren zur identifikation von immunregulatoren, immunregulatoren und deren verwendungen
CN1980957A (zh) 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
CA2574953A1 (en) 2004-07-26 2006-02-09 Dow Global Technolgies Inc. Process for improved protein expression by strain engineering
CA2574881C (en) 2004-08-04 2013-01-08 Amgen Inc. Antibodies to dkk-1
KR101235479B1 (ko) 2004-08-06 2013-02-20 제넨테크, 인크. 바이오마커를 사용한 분석 및 방법
ATE508205T1 (de) 2004-08-06 2011-05-15 Genentech Inc Tests und verfahren unter verwendung von biomarkern
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006059110A2 (en) * 2004-12-02 2006-06-08 Domantis Limited Plad domain peptides with increased serum half life due to conjugation to domain antibodies
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
ATE533058T1 (de) 2005-08-16 2011-11-15 Genentech Inc Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2007095161A2 (en) * 2006-02-14 2007-08-23 New York University Methods and compositions for treating disorders associated with increased bone turnover and osteopenia
EP1854458A1 (de) * 2006-05-08 2007-11-14 IMBA-Institut für Molekulare Biotechnologie GmbH Verwendung einer Verbindung mit RANKL Aktivität
WO2007132512A1 (ja) 2006-05-12 2007-11-22 Keio University 炎症性疾患の検出並びに炎症性疾患の予防又は治療用組成物
WO2008044379A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Modèle animal de perte osseuse
WO2008044378A1 (en) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Reagent containing fused protein of soluble rankl with epitope tag
WO2008044797A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Animal modèle d'ostéopénie
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
JP5444553B2 (ja) 2007-04-27 2014-03-19 フェネックス インコーポレイテッド 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および／または質が改善されている特定の株を同定する方法
CN101772351B (zh) 2007-06-05 2013-01-02 东方酵母工业株式会社 新的骨量增加药
EP2171449A2 (de) * 2007-06-20 2010-04-07 Schering Corporation Gelenkzerstörung-biomarker für die anti-il-17a-therapie von entzündlicher gelenkerkrankung
EA023555B1 (ru) 2007-08-21 2016-06-30 Амген Инк. АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ c-fms ЧЕЛОВЕКА
KR100911852B1 (ko) 2007-11-26 2009-08-11 고려대학교 산학협력단 유세포 분석기를 이용한 신규한 ｒａｎｋ와 ｒａｎｋ리간드의 결합 분석방법
WO2009105934A1 (zh) * 2008-02-27 2009-09-03 上海先导药业有限公司 抗人rankl单克隆抗体
TW201019959A (en) 2008-08-19 2010-06-01 Regeneron Pharma Human antibodies to human RANKL
US8657662B2 (en) 2008-09-04 2014-02-25 Patent Investment & Licensing Company Gaming device having variable speed of play
EP2343087B1 (de) 2008-09-30 2018-07-18 Oriental Yeast Co., Ltd. Neuartiger induktor für chondrozytenproliferation und differenzierungs
CN101712964B (zh) * 2008-10-08 2013-05-08 上海科新生物技术股份有限公司 抑制破骨细胞形成的融合蛋白、其制备方法及药物组合物
BRPI0921837A2 (pt) 2008-11-25 2016-01-12 Biogen Idec Inc anticorpos isolados ou fragmentos de antígeno de ligação dos mesmos que podem se ligar especificamente a um polipeptídio dr6, métodos in vitro de promover a sobrevivência de uma célula do sistema nervoso, usos de um antagonista dr6 e métodos in vitro de inibir a ligação de dr6 com p75
CN101514232B (zh) * 2009-03-25 2013-06-19 上海科新生物技术股份有限公司 一种RANKL-Fc融合蛋白及其制备方法和用途
JP5746018B2 (ja) * 2009-04-16 2015-07-08 国立大学法人 東京大学 抗ｔｍｐｒｓｓ１１ｅ抗体を用いた癌の診断と治療
KR101153393B1 (ko) * 2009-09-21 2012-06-07 고려대학교 산학협력단 점변이 이용한 수용성 재조합 인간 ｒａｎｋ의 효능 향상 및 골 질환 치료용 조성물
EP3372617B1 (de) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Bindungsfusionsproteine, bindungsfusionsproteinarzneimittelkonjugate, xten-arzneimittelkonjugate sowie verfahren zur herstellung und verwendung davon
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
EP2434285A1 (de) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Brustkrebsdiagnose
EP2433644A1 (de) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Brustkrebstherapeutika
CN108192972B (zh) 2010-10-06 2022-09-09 生物医学研究机构基金会 用于乳腺癌转移的诊断、预后和治疗的方法
EP2692359B1 (de) 2011-03-31 2017-06-07 Oriental Yeast Co., Ltd. Krebsimmunitätsverstärker mit einem rankl-antagonisten
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
FR2980711A1 (fr) * 2011-10-03 2013-04-05 Centre Nat Rech Scient Modulation du systeme immunitaire et des cellules stromales via rank
WO2013067639A1 (en) 2011-11-07 2013-05-16 UNIVERSITé LAVAL Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
EP2650682A1 (de) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Asymmetrische Ester von als Schmiermittel geeigneten Fettsäuren
EP2859120B1 (de) 2012-06-06 2018-11-14 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Verfahren zur diagnose und prognose von lungenkrebsmetastasen
ES2744244T3 (es) 2012-10-12 2020-02-24 Inbiomotion Sl Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-MAF
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
SG10201913874TA (en) 2013-03-15 2020-03-30 Biogen Ma Inc Factor ix polypeptide formulations
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
CA2906394A1 (en) 2013-03-15 2014-09-18 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
WO2015018421A1 (en) 2013-08-07 2015-02-12 Rigshospitalet Copenhagen University Hospital Antibodies, compounds and derivatives thereof for use in the treatment of male infertility
WO2015030701A1 (en) * 2013-08-24 2015-03-05 R-Pharm Overseas, Inc. Fully human antibodies against human rankl
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
JP6668241B2 (ja) 2013-09-05 2020-03-18 アムジエン・インコーポレーテツド 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すＦｃ含有分子
CN105980576B (zh) 2013-10-09 2021-07-16 生物医学研究机构基金会 用于源自乳腺癌的骨转移癌的预后和治疗的方法
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
SI3122426T1 (sl) 2014-03-28 2023-04-28 Duke University Zdravljenje raka dojk z uporabo selektivnih modulatorjev estrogenskih receptorjev
MX377275B (es) 2014-05-16 2025-03-07 Amgen Inc Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
WO2016092524A1 (en) 2014-12-11 2016-06-16 Inbiomotion S.L. Binding members for human c-maf
CN104829725A (zh) * 2015-01-21 2015-08-12 武汉友芝友生物制药有限公司 一种双特异性抗体cd133×cd3的构建及应用
KR102871388B1 (ko) 2015-04-29 2025-10-14 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
JP6567083B2 (ja) * 2015-05-18 2019-08-28 イーライ リリー アンド カンパニー 抗ｄｋｋ−１−抗ｒａｎｋｌ二重特異性抗体化合物
CN108064231A (zh) * 2015-05-20 2018-05-22 国立大学法人大阪大学 具有炎性细胞因子分泌抑制活性的寡肽
CA3009350A1 (en) * 2016-01-05 2017-07-13 The Trustees Of Columbia University In The City Of New York Compositions and methods for regulating activity of inhibitor of dna binding-2 (id2) protein
WO2017123642A1 (en) * 2016-01-12 2017-07-20 The Trustees Of The University Of Pennsylvania Methods and uses of osteoclast associated receptor (oscar) for prevention and treatment of osteoarthritis
EP3411066A1 (de) 2016-02-01 2018-12-12 Eli Lilly and Company Parathormon-anti-rankl-antikörperfusionsverbindungen
CA3016894A1 (en) 2016-03-08 2017-09-14 Janssen Biotech, Inc. Gitr antibodies, methods, and uses
KR102571924B1 (ko) 2016-05-25 2023-08-28 인바이오모션 에스.엘. c-MAF 상태에 기초한 유방암의 치료
AU2017294772B2 (en) 2016-07-14 2024-05-02 Scholar Rock, Inc. TGFB antibodies, methods, and uses
BR112019006127A2 (pt) 2016-10-28 2019-06-18 Lilly Co Eli anticorpos anti-rankl e usos destes
SI3565542T1 (sl) 2017-01-05 2024-08-30 Radius Pharmaceuticals, Inc. Polimorfne oblike RAD1901-2HCL
WO2018170099A1 (en) 2017-03-14 2018-09-20 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
CN111565725A (zh) 2017-11-22 2020-08-21 生物运动有限公司 基于c-maf状态的乳腺癌的治疗性处理
SG11202009216YA (en) 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
IL279853B2 (en) 2018-07-04 2025-01-01 Radius Pharmaceuticals Inc Polymorphic forms of RAD 1901-2HCL
US11499928B2 (en) * 2018-08-24 2022-11-15 University Of Wyoming Methods and systems for isochoric measurements using differential scanning calorimetry
WO2020070288A1 (en) 2018-10-05 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
US11279698B2 (en) 2018-11-20 2022-03-22 Cornell University Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
WO2020167855A1 (en) 2019-02-12 2020-08-20 Radius Pharmaceuticals, Inc. Processes and compounds
AU2020355251A1 (en) 2019-09-26 2022-04-21 Amgen Inc. Methods of producing antibody compositions
WO2021149012A1 (en) 2020-01-24 2021-07-29 Radius Health, Inc. Methods of stimulating bone growth with abalopartide and denosumab
CN111793135A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种用于检测血清中rankl含量的抗体对及其用途
EP4162257A1 (de) 2020-06-04 2023-04-12 Amgen Inc. Beurteilung von reinigungsvorgängen eines biotherapeutischen herstellungsverfahrens
EP4229080A1 (de) 2020-10-15 2023-08-23 Amgen Inc. Relative ungepaarte glycane in antikörperherstellungsverfahren
CA3222409A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
CN118139882A (zh) * 2022-03-24 2024-06-04 安济盛生物医药有限公司 骨骼肌肉系统疾病的治疗
EP4507779A1 (de) 2022-04-14 2025-02-19 Institut National de la Santé et de la Recherche Médicale Verfahren zur kontrolle der tumorzellabtötung durch licht
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4710457A (en) * 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
US4710473A (en) * 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
WO1986000922A1 (en) 1984-07-30 1986-02-13 The Salk Institute For Biological Studies Retroviral gene transfer vectors
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US6150090A (en) * 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
EP0273928B1 (de) * 1986-07-18 1997-01-08 The University Of Melbourne Aktives protein in humoraler hyperkalzemia, durch bösartigkeit verursacht
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
CA2071912C (en) * 1990-11-30 2002-10-15 Hanne Bentz Use of a bone morphogenetic protein in synergistic combination with tgf-beta for bone repair
US6121002A (en) * 1990-12-26 2000-09-19 The Rowett Research Institute Method to detect bone and other connective tissue disorders in humans and animals
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en) 1991-05-13 1992-11-14 Masahiko Sato Method for inhibiting bone resorption
MX9204303A (es) * 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int Factor regulador del crecimiento de osteoclasto.
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
KR100283541B1 (ko) * 1991-10-25 2001-03-02 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 신규 사이토킨
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
DE69327582T2 (de) 1992-04-30 2000-08-03 Amgen Inc., Thousand Oaks Methoden zur Behandlung von Interleukin- 1 und - Tumor - Nekrose - Faktor - verursachten Krankheiten
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
ES2198414T3 (es) 1992-10-23 2004-02-01 Immunex Corporation Procedimientos para preparar proteinas oligomericas solubles.
US5578569A (en) * 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
DE69427588T2 (de) * 1993-09-14 2002-04-25 Merck & Co., Inc. HUMANE PROTEIN-TYROSINPHOSPHATASE DECODIERENDE cDNA
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
US5741667A (en) 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
AU4440496A (en) 1995-02-10 1996-08-22 Smithkline Beecham Corporation Use of src SH2 specific compounds to treat a bone resorption disease
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US20030166097A1 (en) * 1995-03-15 2003-09-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US7094564B1 (en) * 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1996028546A1 (en) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
EP2017337A1 (de) * 1995-04-27 2009-01-21 Human Genome Sciences, Inc. Rezeptoren für den menschlichen Tumornekrosefaktor
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
ES2214541T3 (es) 1995-06-07 2004-09-16 Immunex Corporation Muteina de cd40l.
WO1997000317A1 (en) 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
AU6090896A (en) 1995-06-07 1997-01-15 Osteosa Inc. Osteoclast growth regulatory factor
EP1666591B1 (de) * 1995-06-29 2011-03-23 Immunex Corporation Cytokin welches Apoptose induziert
ZA966663B (en) 1995-08-17 1998-02-06 Genentech Inc Traf Inhibitors.
JPH0997808A (ja) 1995-09-29 1997-04-08 Mitsumi Electric Co Ltd ダイボンディング装置
JPH09151434A (ja) 1995-11-24 1997-06-10 Tootetsu:Kk 角形蛇籠の変形防止枠及びその蛇籠の設置方法
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
EP0873405B1 (de) 1996-01-11 2004-09-08 Immunex Corporation Expressionssteigernde sequenzelemente (ease) für eukaryontische expressionssysteme
JPH09217897A (ja) 1996-02-14 1997-08-19 Hitachi Ltd Ｓｆ６貯蔵供給装置、その貯蔵方法及び供給方法
JPH09224803A (ja) 1996-02-21 1997-09-02 Nakajima Cafe Honsha:Kk 蓋付きコーヒーカップ
US5766223A (en) 1996-03-21 1998-06-16 Johnson; Deborah M. Child's teething device
US5710013A (en) 1996-04-19 1998-01-20 Tularik Inc. Tumor necrosis factor receptor associated factor 6 (TRAF6)
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
BR9714401A (pt) 1996-12-13 2000-04-18 Schering Corp Antìgenos de supefìcie de célula de mamìfero; regentes relacionados
AU5901598A (en) * 1996-12-20 1998-07-17 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
ES2144386T5 (es) 1996-12-23 2012-12-07 Immunex Corporation Ligando para el activador del receptor de NF-kappa b, el ligando es miembro de la superfamilia de TNF
US6271349B1 (en) * 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
WO1999058674A2 (en) * 1998-05-14 1999-11-18 Immunex Corporation Method of inhibiting osteoclast activity
IL127115A (en) * 1997-04-15 2013-08-29 Daiichi Sankyo Co Ltd A substance for the treatment of diseases related to bone metabolism problem
ATE363533T1 (de) 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
CA2229449A1 (en) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
EP0980432A1 (de) 1997-05-01 2000-02-23 Amgen, Inc. Chimäre opg-polypeptide.
AU7705098A (en) * 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
US7063960B2 (en) * 1997-12-12 2006-06-20 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
US7019119B2 (en) * 1997-12-12 2006-03-28 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
JPH11266872A (ja) * 1998-03-20 1999-10-05 Suntory Ltd ＮＦ−κＢの活性化を抑制する物質のスクリーニング方法
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
HUP0102492A2 (hu) 1998-06-19 2001-11-28 Smithkline Beecham Corp. Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására
HUP0102782A3 (en) 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
AU6078500A (en) 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
US6252180B1 (en) * 1999-08-09 2001-06-26 Lucent Technologies Inc. Electromagnetic interference cover for a conduit and an electronic equipment chassis employing the same
IL142900A0 (en) 1999-09-03 2002-04-21 Amgen Inc Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
AUPQ314799A0 (en) 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
AU3868001A (en) 2000-02-23 2001-09-03 Amgen Inc Antagonistic selective binding agents of osteoprotegerin binding protein
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
WO2002015846A2 (en) * 2000-08-21 2002-02-28 Smithkline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
JP4212470B2 (ja) * 2001-06-26 2009-01-21 アムジェン フレモント インク． Ｏｐｇｌへの抗体
PL375041A1 (en) 2002-04-05 2005-11-14 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US7157993B2 (en) 2003-09-30 2007-01-02 Rockwell Scientific Licensing, Llc 1:N MEM switch module

Also Published As

Publication number Publication date
EP2314695A2 (de) 2011-04-27
ES2144386T1 (es) 2000-06-16
DE951551T1 (de) 2000-09-14
US20050003391A1 (en) 2005-01-06
EP2314695A3 (de) 2011-12-21
US6242213B1 (en) 2001-06-05
LU91758I2 (fr) 2011-01-24
JP4242913B2 (ja) 2009-03-25
EP0951551B2 (de) 2012-08-08
DE69740107D1 (de) 2011-03-10
US20110200990A1 (en) 2011-08-18
US20020086827A1 (en) 2002-07-04
US6649164B2 (en) 2003-11-18
AU713471C (en) 2002-04-18
EP0946725A2 (de) 1999-10-06
AU713471B2 (en) 1999-12-02
US7932375B2 (en) 2011-04-26
US20140186887A1 (en) 2014-07-03
PT951551E (pt) 2008-10-28
WO1998028424A2 (en) 1998-07-02
JP2007014339A (ja) 2007-01-25
US6740522B2 (en) 2004-05-25
US6017729A (en) 2000-01-25
AU5718498A (en) 1998-07-17
US6537763B2 (en) 2003-03-25
ES2144386T5 (es) 2012-12-07
JP2008113656A (ja) 2008-05-22
US7411050B2 (en) 2008-08-12
US6528482B1 (en) 2003-03-04
US8333963B2 (en) 2012-12-18
JP2002509430A (ja) 2002-03-26
US20140235832A1 (en) 2014-08-21
US20120034690A1 (en) 2012-02-09
US6479635B1 (en) 2002-11-12
DE69738841D1 (de) 2008-08-28
US20130203682A1 (en) 2013-08-08
JP4138013B2 (ja) 2008-08-20
DK0951551T3 (da) 2008-09-01
US20020081720A1 (en) 2002-06-27
ES2144386T9 (es) 2013-02-18
US8569456B2 (en) 2013-10-29
JP2009051862A (ja) 2009-03-12
US20020169117A1 (en) 2002-11-14
DE122010000048I1 (de) 2011-05-05
US6419929B1 (en) 2002-07-16
US20110086033A1 (en) 2011-04-14
EP2003203A1 (de) 2008-12-17
EP2371962A2 (de) 2011-10-05
IL130492A0 (en) 2000-06-01
US20090017033A1 (en) 2009-01-15
US20120178912A1 (en) 2012-07-12
JP5096527B2 (ja) 2012-12-12
US6562948B2 (en) 2003-05-13
US8715683B2 (en) 2014-05-06
US7744886B2 (en) 2010-06-29
AU5618098A (en) 1998-07-17
CA2274987C (en) 2012-01-24
ES2144386T3 (es) 2009-01-16
LU91758I9 (de) 2019-01-02
WO1998028426A2 (en) 1998-07-02
EP2371962A3 (de) 2011-12-21
EP0951551B9 (de) 2012-12-26
US8377690B2 (en) 2013-02-19
US20030175840A1 (en) 2003-09-18
US6838262B1 (en) 2005-01-04
EP0951551B1 (de) 2008-07-16
US7262274B2 (en) 2007-08-28
EP0946725B1 (de) 2011-01-26
CA2274987A1 (en) 1998-07-02
US20020086826A1 (en) 2002-07-04
JP4054354B2 (ja) 2008-02-27
AU713473B2 (en) 1999-12-02
US20080009014A1 (en) 2008-01-10
JP4203105B2 (ja) 2008-12-24
DK0951551T4 (da) 2012-09-10
JP2002509431A (ja) 2002-03-26
EP0951551A2 (de) 1999-10-27
ATE497001T1 (de) 2011-02-15
JP2008133302A (ja) 2008-06-12
JP2010241823A (ja) 2010-10-28
US8153775B2 (en) 2012-04-10
IL130492A (en) 2007-09-20
WO1998028424A3 (en) 1998-09-11

Similar Documents

Publication Publication Date Title
DE69738841D1 (de) Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
ATE187982T1 (de) Cytokine antagoniste
ATE279517T1 (de) Il-17 receptor
DK0760857T3 (da) Receptor for onkostatin M
FI946005L (fi) Glysiinireseptoriantagonisteja ja niiden käyttö
FR2569666B1 (fr) Dispositif permettant de conserver, separes l'un de l'autre, au moins deux produits et d'effectuer leur melange ulterieurement, notamment au moment de l'utilisation
EP0667773A4 (de) Fibrinogen-rezeptor-antagonisten.
FI933810L (fi) Reseptorantagonister av exiterbara aminosyror
ATE114724T1 (de) Antikörper gegen tnf-bindungsprotein i und deren f(ab)-fragmente.
DE69207351D1 (de) Fibrinogen-Rezeptor-Antagoniste
DE69032963D1 (de) (Modifiziertes) hydriertes Dien-Blockcopolymer und dieses enthaltende Zusammensetzung
DE69331175D1 (de) Interleukin-2 Rezeptor Gamma-Kette
IT1228211B (it) Agglomerato combustibile resistente all'acqua, procedimento per la sua preparazione e composizione di materiali usata in tale procedimento.
DK0842132T3 (da) På vand flydende partikelformige materialer, der indeholder mikronæringsstoffer til fytoplankton
FR2695475B1 (fr) Conductivimètre pour mesurer en régime transitoire la conductivité d'un matériau injectable ou non.
EP1005354A4 (de) Peptidmimetika der zytokinrezeptor gammakette
IL99501A0 (en) Interleukin 9 receptors,methods for the use thereof and pharmaceutical compositions containing the same
EP0928419A4 (de) Zusammensetzungen und verfahren zur regulierung der expression des type-i-interleukin-1-rezeptors
NO179550C (no) Tachykinin reseptorantagonister
DE58907320D1 (de) Bituminöse Masse und deren Verwendung.
DE68925335D1 (de) Harzzusammensetzung und ihre Verwendung
DE69230659D1 (de) Polypeptide, die an die schweren Ketten von IL-2-Rezeptoren binden können
DE69003364D1 (de) Einrichtung zum Einfahren von Gewindeverbindungen für Rohrstränge durch Festschrauben und Losdrehen.
SE9400741D0 (sv) A feed weighing device
FI922124A7 (fi) Atsabisykloamideja ja estereitä 5-HT3-reseptorin antagonisteina